DSNKY - Esperion: Establishing A Position Ahead Of The PDUFA Date
Back in May, Esperion Therapeutics (ESPR) announced the FDA set two PDUFA dates in February for the company's two leading products, bempedoic acid and bempedoic acid/ezetimibe combination tablet. Both of these product candidates are looking to be approved to treat elevated low-density lipoprotein cholesterol "LDL-C". What is more, Esperion has roughly $302.2M in cash, cash equivalents, restricted cash, and investment securities available to sell. Back in January, the company was able to close a licensing and collaboration agreement with Daiichi Sankyo Europe (DSNKY) to commercialize bempedoic acid and bempedoic acid/ezetimibe combination